Stereotactic radiosurgery for primary malignant spinal tumors

Area of Science:

• Oncology
• Neurosurgery
• Radiation Oncology

Background:

• Primary malignant spinal tumors are rare and challenging to treat.
• Stereotactic radiosurgery (SRS) is an advanced radiation technique delivering precise, high-dose radiation to tumors.
• Evaluating SRS efficacy and prognostic factors is crucial for optimizing treatment strategies.

Observation:

• A retrospective analysis of 29 patients with primary malignant spinal tumors treated with SRS was conducted.
• Tumor types included chordoma, chondrosarcoma, osteosarcoma, and others.
• SRS was used as primary treatment in 14 cases and as salvage in 15 cases, with a median follow-up of 50 months.

Findings:

• The mean local progression-free survival was 56 months for chordoma and 73 months for sarcoma patients.
• Recurrent presentation was a significant predictor of local progression in spinal sarcomas (P = 0.009).
• No factors correlated with local recurrence in chordoma patients, and no factors affected overall survival.

Implications:

• SRS demonstrates potential for achieving good local control in primary malignant spinal tumors, particularly as postoperative adjuvant or salvage therapy.
• Understanding prognostic factors like recurrent presentation can help tailor treatment for spinal sarcomas.
• Further research is warranted to refine SRS protocols and improve outcomes for these rare tumors.